Abstract

BackgroundPulmonary enteric adenocarcinoma (PEAC) has distinctive clinical outcomes, radiographic, pathological and molecular characteristics. The prognosis of patients with PEAC was poor. However, molecular profiles and therapeutic biomarkers of PEAC remain elusive.MethodsIn the present study, the hospitalized patients with PEAC admitted to Tongji Hospital in Wuhan from January 1, 2014 to November 20, 2020 were retrospectively enrolled and followed until December 10, 2020. Comprehensive genomic profiling of tumor tissue from the PEAC patients were performed and compared with lung adenocarcinoma, colorectal cancer and metastatic colorectal carcinoma. Tumor immune microenvironment analysis were evaluated.ResultsThere were 10 patients with PEAC enrolled. 70% of patients were male and the median age of onset was 63 years (interquartile range, 55–72). There were six early-stage patients (Stage IA to IIB) and four stage IV patients. Molecular analysis revealed the most common gene mutations included TP53 (57%, 4/7) and KRAS (57%, 4/7) mutations. There were 40% mutations occurred in genes encoding receptor tyrosine kinases (RTKs). 100% of patients (8/8) were microsatellite stability (MSS). The median level of TMB was 6.0 (interquartile range, 4.5–7.0) mutations/Mb. Three of 10 patients showed low PD-L1 expression (tumor proportion score < 10%) and the others were PD-L1 negative. A small subset of CD8+, CD3+, CD68+ T cells were observed and were mainly distributed in the cancer stroma.ConclusionThis study demonstrated that PEAC was characterized by low-frequency RTK gene mutation, high KRAS mutation, low PD-L1 expression, low TMB, and low CD8+ T cells infiltration.

Highlights

  • Pulmonary enteric adenocarcinoma (PEAC) has distinctive clinical outcomes, radiographic, pathological and molecular characteristics

  • PEAC and pulmonary invasive mucinous adenocarcinoma showed common histomorphological characteristics featured by columnar cells with mucin production

  • Investigations on molecular profiles of PEAC indicated that it could be used as potential optimal markers for differential diagnosis [3,4,5]

Read more

Summary

Introduction

Pulmonary enteric adenocarcinoma (PEAC) has distinctive clinical outcomes, radiographic, pathological and molecular characteristics. The prognosis of patients with PEAC was poor. Molecular profiles and therapeutic biomarkers of PEAC remain elusive. Pulmonary enteric adenocarcinoma (PEAC) was classified as a rare variant of invasive adenocarcinoma in 2011. PEAC and pulmonary invasive mucinous adenocarcinoma showed common histomorphological characteristics featured by columnar cells with mucin production. PEAC are similar to metastatic colorectal carcinoma (MCC) in histomorphologic and immunohistochemical features with more than 50% enteric pattern. It is currently difficult to identify PEAC based on information from conventional morphology, immunohistochemistry. It is necessary to clinically exclude metastases from colorectal carcinoma before the final diagnosis. Investigations on molecular profiles of PEAC indicated that it could be used as potential optimal markers for differential diagnosis [3,4,5]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call